DOCSLIB.ORG

2018 Southern Regional Meeting

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Abstracts J Investig Med: first published as 10.1136/jim-2017-000697.1 on 1 February 2018. Downloaded from Cardiovascular club I Purpose of study Coronary artery disease (C.A.D.) is one of the highest causes of death in the world. The purpose of this 11:00 AM study is to compare Puerto Rico (P.R.), Hispanic, U.S.A. coun- try, with the U.S.A., in coronary artery disease. Thursday, February 22, 2018 Methods used Compare a population of Hispanics with the high LDL levels with normal total cholesterol and HDL in P. R. and the U.S.A. The study population was 1000 patients. 1 A POSSIBLE ROLE FOR GENETICS IN CARDIOVASCULAR The U.S.A. health statistics and P.R. Department of Health DISEASE AMONG THE ACADIANS was used for comparison. AE Tedesco*, Z Haq, KL Di Losa, MJ Ali, P Gregory. LSUHSC – New Orleans, New Orleans, Summary of results Studying the lipid profile of Puerto Rico LA population, we found that the mean value of LDL lipoprotein is high (±104 mg/dl) with similar cholesterol and HDL levels 10.1136/jim-2017-000697.1 in both societies; still the coronary disease (CAD) incidence is lower than the U.S.A. (20%–30%). Investigators from the U.P. Purpose of study It is well documented that the Louisiana Aca- R. reported the genetic admixture of this Hispanic population. ‘ ’ dians ( Cajuns ) experience a disproportionate risk for some They reported the admixture consisted of 3 genes called pro- genetic diseases due to a genetic founder effect.Furthermore, cer- tective against C.A.D. tain founder populations show a predisposition for developing Conclusions C.A.D. is an inflammatory process involving heart disease.The current study was designed to determine both inflammation of the endothelial cells, macrophages and other the population prevalence of cardiovascular disease in the Acadian cells. Probably, this admixture protects the endothelial cells region and to determine whether the prevalence of early cardio- against an aggressive inflammatory process and excessive oxi- vascular disease is increased among the Cajun population. dative stress. The observation of stitziel-Washington University Methods used We obtained descriptive information via the which described ANGPTL3 gene which produces low choles- electronic medical record of 345 consecutive patients previ- terol levels and absent plaques in the coronary arteries sup- ously diagnosed with early onset (age <50) cardiovascular dis- port our hypothesis. ease (CVD) who presented to University Hospital and Clinics Cardiology Clinic (June 2015–July 2016). The patients con- sisted of 184 African Americans (97 females and 87 males) and 161 Caucasians (74 females and 87 males).For this study, 3 OBESITY IS ASSOCIATED WITH AORTIC DIALATION IN cardiovascular diseases included: coronary artery disease, MARFAN’S SYNDROME HTN, myocardial infarction, and CHF. Demographics, vital signs, lipid panel results, medications, family history, date of SD Grado*, C Watson, WF Campbell, S Kiparizoska, A Thibodeaux, C Richards, TA Skelton, CVD diagnosis, and past medical history were collected for all MR McMullan, ME Hall. University of Mississippi Medical Centre, Jackson, MS patients.The data on the (161) Caucasian patients were then 10.1136/jim-2017-000697.3 stratified into either Cajun-identified or non-Cajun by compar- ing each patient’s last name to a standardised list of most ’ Purpose of study Marfan s Syndrome (MS), a connective tissue http://jim.bmj.com/ popular Cajun last names. Means for each variable between disorder characterised by a slender build and long limbs, is the two groups were compared using independent t-tests. associated with aortopathy and aortic dissection. Obesity is Summary of results The results of our analysis revealed that associated with haemodynamic and metabolic abnormalities Cajun-identified patients were diagnosed with a CVD at a signifi- such as hypertension, hyperglycemia, inflammation and aortic cantly younger age (40±8 years) than were non-Cajun patients stiffness that may adversely affect the aorta. We aimed to (44±4 years,p=0.03).There were no significant differences determine if obesity is associated with aortic dilation in MS between the Cajun-identified and non-Cajun groups with regard patients living in an obese environment. on September 25, 2021 by guest. Protected copyright. to BMI, blood pressure, HDL and LDL levels, family history of Methods used We retrospectively analysed anthropometric and CVD, or smoking/alcohol use history. Cajun patients had lower tri- echocardiographic data from 61 MS patients from the Univer- glyceride levels (184.6±140.4) than non-Cajun whites (210.3 sity of Mississippi Medical Centre from the past 5 years. Mul- ±153.1) although whis was not statistically significant. tivariable linear regression was used to assess the association Conclusions Our results show that patients of Cajun ancestry of body mass index (BMI) with aortic root diameter measured were diagnosed with cardiovascular disease at a younger age on the parasternal long axis view at the sinuses of Valsalva on than their non-Cajun counterparts.This intriguing finding sug- transthoracic echocardiogram. gests that genetic predisposition may contribute to environ- Summary of results The mean BMI of our MS patients was mental/behavioural factors in development of CVD. Further higher compared with historically published data on MS study is needed to determine the generalizability and the cause patients (24.5 kg/m2 vs 20.1 kg/m2). This corresponds with of this pathology. the high prevalence of overweight (BMI 25.0 to <30 kg/m2) and obesity (BMI 30.0 kg/m2) in the state of Mississippi and suggests that it extends to the congenital heart population. 2 STILL WITH HIGHER LDL LEVELS-HISPANICS IN PUERTO Mean aortic root dimensions were increased in overweight RICO SHOWS A LOWER CORONARY ARTERY DISEASE (40.9±5.1 mm) and obese MS patients (51.5±12.0 mm) com- THAN THE USA-EXPLAINED BY GENETIC ADMIXTURE pared to normal weight (37.0±6.8 mm) or underweight (38.1 ±8.6 mm) patients. Aortic root diameter increased with 1JE Muñoz*, 1P Elosegui, 1C Melendez, 1,2PI Altieri, 1,2HL Banchs. 1University of Puerto Rico, Medical Sciences Campus, San Juan, PR; 2Cardiovascular Centre of Puerto Rico and increasing BMI, independent of age, sex, race, systolic blood the Caribbean, San Juan, PR pressure and height (p=0.06). Conclusions Patients with MS tend to be tall and lean; how- 10.1136/jim-2017-000697.2 ever, in Mississippi, a state with high rates of obesity, they 354 J Investig Med 2018;66:351–640 Abstracts J Investig Med: first published as 10.1136/jim-2017-000697.1 on 1 February 2018. Downloaded from have higher mean BMIs when compared to published data. Abstract 4 Table 2 Chi square analysis; patients admitted on a Higher BMI was associated with larger aortic root diameters weekend/holiday versus weekday in our single-centre study. Further assessment of rates of aortic Admitted on a Weekend or 20 24 dilation in MS patients with differing BMIs is needed to Holiday determine if overweight and obesity exacerbate aortic dilation in MS. Admitted on a Weekday 26 103 4 BARRIERS TO EARLY CARDIAC CATHETERIZATION IN HIGH RISK NSTEMI PATIENTS 5 INTRAVENOUS IRON ADMINISTRATION REDUCES C Basman*, A Bhandary, J Daibes, P Sayegh, S Lebrun, N Coplan. Lenox Hill Hospital, New FIBROBLAST GROWTH FACTOR 23 LEVELS IN CHRONIC York, NY KIDNEY DISEASE B Panwar*, O Gutierrez. University of Alabama, Hoover, AL 10.1136/jim-2017-000697.4 10.1136/jim-2017-000697.5 Purpose of study The purpose of this study is to analyse bar- riers for patients with high risk NSTEMI to receive an early Purpose of study Higher fibroblast growth factor 23 (FGF23) invasive treatment strategy. is associated with higher risk of heart disease and mortality in Methods used We conducted a retrospective chart review chronic kidney disease (CKD). Recently, iron deficiency has designed to evaluate whether patients with high risk NSTEMI been linked to elevated FGF23 levels. We examined whether are receiving an early invasive (within 1 day of admission) or treatment with intravenous iron reduces FGF23 in individuals – delayed invasive (1 3 days after admission) strategy. with CKD. Summary of results The study included 173 patients that pre- Methods used 10 participants with stage 3/4 CKD (eGFR 15– sented to the Emergency Department with high risk NSTEMI. 59 ml/min) and scheduled to receive intravenous iron (Feru- There were 46 patients (average age 64.5 years) in the moxytol) were enrolled in a single-arm study. The primary delayed invasive arm, and 127 patients (average age 63.2 outcome variable was change in intact FGF23 (iFGF23) or c- years) in the early invasive arm analysed. Patients receiving a terminal FGF23 (cFGF23) levels. Study samples were drawn delayed invasive strategy were more likely to have a history at baseline and 2 weeks after iron administration. Paired t-test of atrial fibrillation (AF) and to be on anticoagulation (table analysis was used to examine change in log transformed 1). Patients admitted on weekend/holiday were more likely to iFGF23 and cFGF23 over time. have delayed invasive compared to patients admitted during Summary of results At baseline, mean estimated glomerular fil- the week (table 2). tration rate, mean serum haemoglobin, mean serum ferritin, Conclusions It is important to recognise barriers to prompt mean percent transferrin saturation and mean serum phospho- cardiac catheterization and to make hospital system adjust- rus were 29.5 (±0.5) ml/min, 8.8 (±1.5) g/dL, 54.8 (±41.6) ments for optimal treatment of patients with NSTEMI. ng/ml, 14(±11.4)%, and 3.9 (±0.5) mg/dL respectively. There http://jim.bmj.com/ was a significant reduction in mean serum iFGF23 concentra- Abstract 4 Table 1 Chi square analysis; baseline features tion (17.7%) at 2 weeks post iron infusion (two tailed p=0.022).
Recommended publications
  • Table 2. Significant

    Table 2. Significant

    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
  • Regulation of Xenobiotic and Bile Acid Metabolism by the Anti-Aging Intervention Calorie Restriction in Mice

    Regulation of Xenobiotic and Bile Acid Metabolism by the Anti-Aging Intervention Calorie Restriction in Mice

    REGULATION OF XENOBIOTIC AND BILE ACID METABOLISM BY THE ANTI-AGING INTERVENTION CALORIE RESTRICTION IN MICE By Zidong Fu Submitted to the Graduate Degree Program in Pharmacology, Toxicology, and Therapeutics and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Dissertation Committee ________________________________ Chairperson: Curtis Klaassen, Ph.D. ________________________________ Udayan Apte, Ph.D. ________________________________ Wen-Xing Ding, Ph.D. ________________________________ Thomas Pazdernik, Ph.D. ________________________________ Hao Zhu, Ph.D. Date Defended: 04-11-2013 The Dissertation Committee for Zidong Fu certifies that this is the approved version of the following dissertation: REGULATION OF XENOBIOTIC AND BILE ACID METABOLISM BY THE ANTI-AGING INTERVENTION CALORIE RESTRICTION IN MICE ________________________________ Chairperson: Curtis Klaassen, Ph.D. Date approved: 04-11-2013 ii ABSTRACT Calorie restriction (CR), defined as reduced calorie intake without causing malnutrition, is the best-known intervention to increase life span and slow aging-related diseases in various species. However, current knowledge on the exact mechanisms of aging and how CR exerts its anti-aging effects is still inadequate. The detoxification theory of aging proposes that the up-regulation of xenobiotic processing genes (XPGs) involved in phase-I and phase-II xenobiotic metabolism as well as transport, which renders a wide spectrum of detoxification, is a longevity mechanism. Interestingly, bile acids (BAs), the metabolites of cholesterol, have recently been connected with longevity. Thus, this dissertation aimed to determine the regulation of xenobiotic and BA metabolism by the well-known anti-aging intervention CR. First, the mRNA expression of XPGs in liver during aging was investigated.
  • Flavin-Containing Monooxygenases: Mutations, Disease and Drug Response Phillips, IR; Shephard, EA

    Flavin-Containing Monooxygenases: Mutations, Disease and Drug Response Phillips, IR; Shephard, EA

    Flavin-containing monooxygenases: mutations, disease and drug response Phillips, IR; Shephard, EA For additional information about this publication click this link. http://qmro.qmul.ac.uk/jspui/handle/123456789/1015 Information about this research object was correct at the time of download; we occasionally make corrections to records, please therefore check the published record when citing. For more information contact [email protected] Flavin-containing monooxygenases: mutations, disease and drug response Ian R. Phillips1 and Elizabeth A. Shephard2 1School of Biological and Chemical Sciences, Queen Mary, University of London, Mile End Road, London E1 4NS, UK 2Department of Biochemistry and Molecular Biology, University College London, Gower Street, London WC1E 6BT, UK Corresponding author: Shephard, E.A. ([email protected]). and, thus, contribute to drug development. This review Flavin-containing monooxygenases (FMOs) metabolize considers the role of FMOs and their genetic variants in numerous foreign chemicals, including drugs, pesticides disease and drug response. and dietary components and, thus, mediate interactions between humans and their chemical environment. We Mechanism and structure describe the mechanism of action of FMOs and insights For catalysis FMOs require flavin adenine dinucleotide gained from the structure of yeast FMO. We then (FAD) as a prosthetic group, NADPH as a cofactor and concentrate on the three FMOs (FMOs 1, 2 and 3) that are molecular oxygen as a cosubstrate [5,6]. In contrast to most important for metabolism of foreign chemicals in CYPs FMOs accept reducing equivalents directly from humans, focusing on the role of the FMOs and their genetic NADPH and, thus, do not require accessory proteins.
  • New Jersey Chapter American College of Physicians

    New Jersey Chapter American College of Physicians

    NEW JERSEY CHAPTER AMERICAN COLLEGE OF PHYSICIANS ASSOCIATES ABSTRACT COMPETITION 2015 SUBMISSIONS 2015 Resident/Fellow Abstracts 1 1. ID CATEGORY NAME ADDITIONAL PROGRAM ABSTRACT AUTHORS 2. 295 Clinical Abed, Kareem Viren Vankawala MD Atlanticare Intrapulmonary Arteriovenous Malformation causing Recurrent Cerebral Emboli Vignette FACC; Qi Sun MD Regional Medical Ischemic strokes are mainly due to cardioembolic occlusion of small vessels, as well as large vessel thromboemboli. We describe a Center case of intrapulmonary A-V shunt as the etiology of an acute ischemic event. A 63 year old male with a past history of (Dominik supraventricular tachycardia and recurrent deep vein thrombosis; who has been non-compliant on Rivaroxaban, presents with Zampino) pleuritic chest pain and was found to have a right lower lobe pulmonary embolus. The deep vein thrombosis and pulmonary embolus were not significant enough to warrant ultrasound-enhanced thrombolysis by Ekosonic EndoWave Infusion Catheter System, and the patient was subsequently restarted on Rivaroxaban and discharged. The patient presented five days later with left arm tightness and was found to have multiple areas of punctuate infarction of both cerebellar hemispheres, more confluent within the right frontal lobe. Of note he was compliant at this time with Rivaroxaban. The patient was started on unfractionated heparin drip and subsequently admitted. On admission, his vital signs showed a blood pressure of 138/93, heart rate 65 bpm, and respiratory rate 16. Cardiopulmonary examination revealed regular rate and rhythm, without murmurs, rubs or gallops and his lungs were clear to auscultation. Neurologic examination revealed intact cranial nerves, preserved strength in all extremities, mild dysmetria in the left upper extremity and an NIH score of 1.
  • Hanna Joleen 2018 Thesis.Pdf

    Hanna Joleen 2018 Thesis.Pdf

    Validation of an In Vitro Mutagenicity Assay Based on Pulmonary Epithelial Cells from the Transgenic MutaMouse: Intra-Laboratory Variability and Metabolic Competence By: Joleen Hanna, B.Sc. A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science In Biology Specializing in Chemical and Environmental Toxicology Supervisor: Dr. Paul White (University of Ottawa) Thesis Advisory Committee: Dr. Frances Pick (University of Ottawa) Dr. Iain Lambert (Carleton University) University of Ottawa Ontario, Canada March 2018 © Joleen Hanna, Ottawa, Canada, 2018 Abstract: Genetic toxicity tests used for regulatory screening must be rigorously validated to ensure accuracy, reliability and relevance. Hence, prior to establishment of an internationally- accepted test guideline, a new assay must undergo multi-stage validation. An in vitro transgene mutagenicity assay based on an immortalized cell line derived from MutaMouse lung (i.e., FE1 cells) is currently undergoing formal validation. FE1 cells retain a lacZ transgene in a λgt10 shuttle vector that can be retrieved for scoring of chemically-induced mutations. This work contributes to validation of the in vitro transgene (lacZ) mutagenicity assay in MutaMouse FE1 cells. More specifically, the work includes an intra-laboratory variability study, and a follow-up study to assess the endogenous metabolic capacity of FE1 cells. The former is essential to determine assay reliability, the latter to define the range of chemicals that can be reliably screened without an exogenous metabolic activation mixture (i.e., rat liver S9). The intra- laboratory variability assessment revealed minimal variability; thus, assay reproducibility can be deemed acceptable. Assessment of metabolic capacity involved exposure of FE1 cells to 5 known mutagens, and subsequent assessment of changes in the expression of genes involved in xenobiotic metabolism; induced transgene mutant frequency (±S9) was assessed in parallel.
  • Supermicar Data Entry Instructions, 2007 363 Pp. Pdf Icon[PDF

    Supermicar Data Entry Instructions, 2007 363 Pp. Pdf Icon[PDF

    SUPERMICAR TABLE OF CONTENTS Chapter I - Introduction to SuperMICAR ........................................... 1 A. History and Background .............................................. 1 Chapter II – The Death Certificate ..................................................... 3 Exercise 1 – Reading Death Certificate ........................... 7 Chapter III Basic Data Entry Instructions ....................................... 12 A. Creating a SuperMICAR File ....................................... 14 B. Entering and Saving Certificate Data........................... 18 C. Adding Certificates using SuperMICAR....................... 19 1. Opening a file........................................................ 19 2. Certificate.............................................................. 19 3. Sex........................................................................ 20 4. Date of Death........................................................ 20 5. Age: Number of Units ........................................... 20 6. Age: Unit............................................................... 20 7. Part I, Cause of Death .......................................... 21 8. Duration ................................................................ 22 9. Part II, Cause of Death ......................................... 22 10. Was Autopsy Performed....................................... 23 11. Were Autopsy Findings Available ......................... 23 12. Tobacco................................................................ 24 13. Pregnancy............................................................
  • High-Altitude Adaptation in Rhesus Macaques 4 5 Zachary A

    High-Altitude Adaptation in Rhesus Macaques 4 5 Zachary A

    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.19.104380; this version posted May 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Article Type: Letter 2 3 High-altitude adaptation in rhesus macaques 4 5 Zachary A. Szpiech† 6 Department of Biological Sciences 7 Auburn University 8 Auburn, AL 36842, USA 9 [email protected] 10 11 Taylor E. Novak* 12 Department of Biological Sciences 13 Auburn University 14 Auburn, AL 36842, USA 15 [email protected] 16 17 Nicholas P. Bailey* 18 Department of Biological Sciences 19 Auburn University 20 Auburn, AL 36842, USA 21 [email protected] 22 23 Laurie S. Stevison† 24 Department of Biological Sciences 25 Auburn University 26 Auburn, AL 36842, USA 27 [email protected] 28 29 †CorresponDence: [email protected], [email protected] 30 *Equal Contribution 31 32 Running Title: High-altitude adaptation in rhesus macaques 33 34 Keywords: Adaptation, high-altitude, EGLN1, selection, macaque, macaca mulatta 35 36 Abstract Word Count (300 max): 216 37 Total Word Count (5000 max): 3813 38 39 40 41 42 43 44 45 46 47 48 49 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.05.19.104380; this version posted May 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
  • Glucocorticoids Are Not Always Deleterious for Bone

    Glucocorticoids Are Not Always Deleterious for Bone

    CLINICAL VIGNETTE JBMR Glucocorticoids Are Not Always Deleterious for Bone Antoon HJM van Lierop, Neveen AT Hamdy, and Socrates E Papapoulos Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands ABSTRACT A 23-year-old man with the rare sclerosing bone disorder van Buchem disease presented with progressively worsening headaches that eventually became persistent and associated with papilledema. Increased intracranial pressure was diagnosed, and the patient had a ventriculoperitoneal drain inserted as well as simultaneously receiving treatment with prednisone. Before starting treatment, there was biochemical evidence for increased bone turnover and for steady increases in bone mineral density (BMD) at the spine and total hip despite the patient having reached his peak height of 197 cm at the age of 19 years. Treatment with prednisone for 2 years resulted in biochemical and histologic suppression of bone formation as well as of bone resorption and arrest of further bone accumulation. Our data suggest that glucocorticoids (GCs) may represent an attractive alternative to the high-risk surgical approaches used in the management of patients with progressive sclerosing bone disorders. Our findings also suggest that whereas sclerostin may not be required for the action of GCs on bone formation, it may well be important for the action of GCs on bone resorption. The exact mechanism by which sclerostin may be involved in the regulation of bone resorption is as yet to be explored. ß 2010 American Society for Bone and Mineral Research. KEY WORDS: BONE RESORPTION; BONE FORMATION; VAN BUCHEM DISEASE; PREDNISONE; SCLEROSTIN Introduction We present here sequential observations of a patient with van Buchem disease with life-threatening increased intracranial an Buchem disease is a rare bone sclerosing disorder pressure who was treated successfully with prednisone.
  • FMO3) As a Novel Genetic Determinant of Acetaminophen (APAP) Induced Hepatotoxicity Swetha Rudraiah University of Connecticut - Storrs, Swetha.Rudraiah@Uconn.Edu

    FMO3) As a Novel Genetic Determinant of Acetaminophen (APAP) Induced Hepatotoxicity Swetha Rudraiah University of Connecticut - Storrs, [email protected]

    University of Connecticut OpenCommons@UConn Doctoral Dissertations University of Connecticut Graduate School 8-4-2014 Characterization of Flavin-containing Monooxygenase-3 (FMO3) as a Novel Genetic Determinant of Acetaminophen (APAP) Induced Hepatotoxicity Swetha Rudraiah University of Connecticut - Storrs, [email protected] Follow this and additional works at: https://opencommons.uconn.edu/dissertations Recommended Citation Rudraiah, Swetha, "Characterization of Flavin-containing Monooxygenase-3 (FMO3) as a Novel Genetic Determinant of Acetaminophen (APAP) Induced Hepatotoxicity" (2014). Doctoral Dissertations. 506. https://opencommons.uconn.edu/dissertations/506 Characterization of Flavin-containing Monooxygenase-3 (FMO3) as a Novel Genetic Determinant of Acetaminophen (APAP) Induced Hepatotoxicity Swetha Rudraiah, Ph.D. University of Connecticut, 2014 Mice pretreated with a mild toxic dose of acetaminophen (APAP) acquire resistance to a second, higher APAP dose. This phenomenon is termed APAP autoprotection and the exact mechanism by which such resistance develops is not clearly known. Given the prevalence of APAP- hepatotoxicity and the human health impact of this potentially hepatotoxic agent, a further understanding of the mechanism(s) involved in such protection are of considerable significance and could lead to new modalities of treatment of acute drug-induced liver injury. The work presented in this thesis investigates FMO3 gene expression during APAP-induced liver injury as well as the functional significance of FMO3 over-expression during APAP- induced liver injury. Furthermore, FMO3 gene regulation during oxidative stress conditions is also examined. Acetaminophen treatment resulted in up-regulation of liver Fmo3 protein in male mice. Female mice express higher liver Fmo3 than males and are highly resistant to APAP hepatotoxicity.

  • Drosophila and Human Transcriptomic Data Mining Provides Evidence for Therapeutic

    Drosophila and human transcriptomic data mining provides evidence for therapeutic mechanism of pentylenetetrazole in Down syndrome Author Abhay Sharma Institute of Genomics and Integrative Biology Council of Scientific and Industrial Research Delhi University Campus, Mall Road Delhi 110007, India Tel: +91-11-27666156, Fax: +91-11-27662407 Email: [email protected] Nature Precedings : hdl:10101/npre.2010.4330.1 Posted 5 Apr 2010 Running head: Pentylenetetrazole mechanism in Down syndrome 1 Abstract Pentylenetetrazole (PTZ) has recently been found to ameliorate cognitive impairment in rodent models of Down syndrome (DS). The mechanism underlying PTZ’s therapeutic effect is however not clear. Microarray profiling has previously reported differential expression of genes in DS. No mammalian transcriptomic data on PTZ treatment however exists. Nevertheless, a Drosophila model inspired by rodent models of PTZ induced kindling plasticity has recently been described. Microarray profiling has shown PTZ’s downregulatory effect on gene expression in fly heads. In a comparative transcriptomics approach, I have analyzed the available microarray data in order to identify potential mechanism of PTZ action in DS. I find that transcriptomic correlates of chronic PTZ in Drosophila and DS counteract each other. A significant enrichment is observed between PTZ downregulated and DS upregulated genes, and a significant depletion between PTZ downregulated and DS dowwnregulated genes. Further, the common genes in PTZ Nature Precedings : hdl:10101/npre.2010.4330.1 Posted 5 Apr 2010 downregulated and DS upregulated sets show enrichment for MAP kinase pathway. My analysis suggests that downregulation of MAP kinase pathway may mediate therapeutic effect of PTZ in DS. Existing evidence implicating MAP kinase pathway in DS supports this observation.
  • Heterotaxy: Associated Conditions and Hospital- Based Prevalence in Newborns Angela E

    Heterotaxy: Associated Conditions and Hospital- Based Prevalence in Newborns Angela E

    May/June 2000. Vol. 2 . No. 3 Heterotaxy: Associated conditions and hospital- based prevalence in newborns Angela E. Lin, MD',~,*, Baruch S. Ticho, MD, phD3j4,Kara Houde, MA1,Marie-Noel Westgate, ME^', and Lewis B. Holmes, MD',~,~ Purpose: To provide insight into the possible etiology and prevalence of heterotaxy, we studied conditions associated with heterotaxy in a consecutive hospital population of newborns. Methods: From 1972 to March, 1999 (except February 16, 1972 to December 31, 1978), 58 cases of heterotaxy were ascertained from a cohort of 201,084 births in the ongoing Active Malformation Surveillance Program at the Brigham and Women's Hospital. This registry includes livebirths, stillbirths, and elective abortions. Prevalence among nontransfers (i.e., patients whose mothers had planned delivery at this hospital) was calculated as approximately 1per 10,000 total births (20 of 201,084). Results: We analyzed a total of 58 patients consisting of 20 (34%) nontransfers and 38 (66%) transfers. Patients were categorized by spleen status as having asplenia (7 nontransfers, 25 total), polysplenia (8, 20), right spleen (4, ll),normal left (0, I), and unknown (1, 0). Among the 20 nontransfer and 59 total heterotaxy patients, the following associated medical conditions were present: chromosome abnormality (1nontransfer, 2 total), suspected Mendelian or chromosome microdeletion disorder (1nontransfer, 6 total), and maternal insulin- dependent diabetes mellitus (1 nontransfer, 2 total). There were 6 twins (1 member each from 6 twin pairs including 1dizygous, 4 monozygous, 1conjoined; 2 were nontransfers). An associated condition occurred in 5 (25%) nontransfer and 16 (28%) total patients, or among 10 of 53 singleton births (19%).
  • Identification of Nondiabetic Heart Failure‑Associated Genes by Bioinformatics Approaches in Patients with Dilated Ischemic Cardiomyopathy

    Identification of Nondiabetic Heart Failure‑Associated Genes by Bioinformatics Approaches in Patients with Dilated Ischemic Cardiomyopathy

    2602 EXPERIMENTAL AND THERAPEUTIC MEDICINE 11: 2602-2608, 2016 Identification of nondiabetic heart failure‑associated genes by bioinformatics approaches in patients with dilated ischemic cardiomyopathy ANZHONG YU1, JINGYAO ZHANG2, HAIYAN LIU3, BING LIU1 and LINGDONG MENG1 1Department of Cardiology, Jinan No. 4 People's Hospital, Jinan, Shandong 250031; 2Department of Blood Purification, Jinan Infectious Disease Hospital, Jinan, Shandong 250021; 3Department of Internal Medicine, Jinan Minzu Hospital, Jinan, Shandong 250014, P.R. China Received January 26, 2015; Accepted March 3, 2016 DOI: 10.3892/etm.2016.3252 Abstract. Heart failure (HF) is a common pathological conclusion, the two DEGs, NPPA and SERPINE1, may be condition affecting 4% of the worldwide population. important in the pathogenesis of HF and may be used for the However, approaches for predicting or treating nondiabetic diagnosis and treatment of HF. HF (ND-HF) progression are insufficient. In the current study, the gene expression profile GSE26887 was analyzed, Introduction which contained samples from 5 healthy controls, 7 diabetes mellitus-HF patients and 12 ND-HF patients with dilated Heart failure (HF), also known as chronic HF, is one of the ischemic cardiomyopathy. The dataset of 5 healthy controls major causes of mortality affecting approximately 4% of the and 12 ND-HF patients was normalized with robust multichip world's population, while the prevalence of this condition is average analysis and the differentially expressed genes (DEGs) currently increasing (1,2). In addition to the widely known were screened by unequal variance t-test and multiple-testing risk factor of glucose abnormalities (observed in ~43% of HF correction. In addition, the protein-protein interaction patients) (3), HF can also result from certain other factors, (PPI) network of the upregulated and downregulated genes which is classified as nondiabetic HF (ND‑HF) and is based was constructed using the Search Tool for the Retrieval of on a complicated pathological mechanism (4,5).